Travere Therapeutics Company Insiders

Travere Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2614) % which means that it has lost $0.2614 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7994) %, meaning that it created substantial loss on money invested by shareholders. Travere Therapeutics' management efficiency ratios could be used to measure how well Travere Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.15 in 2025. Return On Capital Employed is likely to rise to -0.67 in 2025. At this time, Travere Therapeutics' Total Current Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 50.9 M in 2025, whereas Total Assets are likely to drop slightly above 461.7 M in 2025. Common Stock Shares Outstanding is likely to drop to about 45.7 M in 2025. Net Loss is likely to rise to about (238.1 M) in 2025

Travere Therapeutics Workforce Comparison

Travere Therapeutics Profit Margins

The company has Profit Margin (PM) of (1.73) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.89) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.89.

Travere Therapeutics Insider Trading History

Travere Therapeutics Notable Stakeholders

The success or failure of an entity such as Travere Therapeutics often depends on how effective the management is. Travere Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Travere management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Travere management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Travere Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Travere Therapeutics. Check Travere Therapeutics' Beneish M Score to see the likelihood of Travere Therapeutics' management manipulating its earnings.

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.